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Key Points
• AICC has been used
since 1977 to control
bleeding in patients
with hemophilia with
inhibitors.
• AICC is associated
with a low incidence of
TEEs, especially when
administered
prophylactically.
Anti-inhibitor coagulant complex (AICC), an activatedprothrombin complex concentrate, has
been available for the treatment of patients with inhibitors since 1977, and thromboembolic
events (TEEs) have been reported after infusion of AICC in patients with congenital or
acquired hemophilia. With the aim of estimating the TEE incidence rate (IR) related to AICC
exposure in these patients, a systematic review of the literature was carried out in Medline,
according to PRISMA guidelines, from inception date to March 2017. The IR of TEEs was
estimated throughameta-analytic approachbyusingageneralized linearmixedmodel based
on a Poisson distribution. Thirty-nine studies were included (1980-2016). Overall, 46 TEEs
were reported; of these, 13 were reported as disseminated intravascular coagulations, 11 as
myocardial infarctions, and 3 as thrombotic cerebrovascular accidents. The pooled TEE IR
was 2.87 (95% conﬁdence interval [CI], 0.32-25.40) per 100 000 AICC infusions (5.42 in
retrospective studies [95% CI, 0.92-31.82]; 1.09 in prospective studies [95% CI, 0.01-238.77]).
The TEE rate was 5.09 (95% CI, 0.01-1795.60) per 100 000 AICC infusions administered on
demand, whereas no TEEswere reported with prophylaxis. Interestingly, the estimated IR in
patients with congenital hemophilia was ,0.01 per 100 000 infusions. These ﬁndings
provide robust evidence of safety of AICC over almost 40 years of published studies.
Introduction
The development of factor VIII (FVIII) inhibitory antibodies is a major challenge in the treatment of hemophilia,
because it hinders FVIII replacement for the treatment and prevention of bleeding events.1 Two products are
currently available to control bleeding in patients with inhibitors: anti-inhibitor coagulant complex (AICC), an
activated prothrombin complex concentrate (FEIBA [FVIII inhibitor bypassing activity] NF; Shire, Lexington,
KY) and recombinant activated factor VII (NovoSeven; Novo Nordisk, Bagsvaerd, Denmark). Both agents
have shown similar efficacy, with some patients responding better to 1 product than to the other.2 Both
agents have been associated with the development of thromboembolic events (TEEs).3
AICC has been used for.40 years to control bleeding in patients with hemophilia with high-titer inhibitors.
It is a plasma-derived concentrate that contains various prothrombin complex coagulation factors, in their
zymogenic and enzymatic forms, and natural anticoagulant factors in a hemostatic balance.4
The aim of this study was to estimate the TEE incidence rate (IR) in patients with congenital hemophilia
with inhibitors or acquired hemophilia exposed to AICC, using a meta-analytic approach based on
published scientific literature.
Methods
We performed a literature search in MedLine using PubMed from its inception date to 23 March 2017
using the following terms: “hemophilia A,” “hemophilia B,” “blood coagulation factors,” “FEIBA,” and
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“CS849DUN3M” (ie, FEIBA US Food and Drug Administration
registration number). The full research string was: (((“hemophilia A”
[MeSH Terms] OR “hemophilia B” [MeSH terms] OR (“haemophilia
A” [tiab] OR “hemophilia A” [tiab] OR “haemophilia B” [tiab] OR
“hemophilia B” [tiab])) AND “blood coagulation factors” [MeSH
terms] AND (“FEIBA” [tiab] OR “FEIBA” [supplementary concept]
OR “CS849DUN3M” [RN])) NOT (“case reports” [publication type]
OR “letter” [publication type])) NOT (animal [MeSH terms] NOT
human [MeSH terms]). For the sake of completeness, we further
reviewed the references of all relevant retrieved articles to identify
additional published studies. Prospective and retrospective, inter-
ventional and noninterventional studies on patients with hemophilia
A or B with inhibitors or with acquired hemophilia treated with AICC
reporting safety data were included in the meta-analysis.
Two of the authors (M.R. and P.A.C.) independently evaluated
eligibility of all the studies retrieved from the electronic literature
search. Two other reviewers (A.G. and R.C.) were also involved to
reach consensus in case of disagreement.
For each included study, we extracted the following data: first
author last name, publication year, geographic area of the study,
study design (prospective or retrospective, interventional or non-
interventional), hemophilia type (A or B, congenital or acquired),
treatment modality (on demand, prophylaxis, or surgery), number of
patients treated with AICC and their mean age if reported, number
of patients reporting TEEs together with the total number and type
of TEEs, and estimated number of AICC infusions.
Exposure to AICC was mandatory to compute the IR of TEEs. If the
number of AICC infusions was not detailed in the publication, the
number of infusions was estimated according to the treatment
modality (on demand, prophylaxis, or surgery) and calculated based
on the mean duration of treatment and/or the mean overall dose per
kilogram of body weight reported. When not otherwise specified,
2 AICC infusions were assumed for each on-demand bleeding
treatment.2,5
Given that TEEs are rare, standard statistical meta-analytic methods
cannot be applied. In fact, standard errors from studies reporting
0 TEEs cannot be estimated unless a continuity correction factor is
used. To overcome this limitation, we estimated study-specific TEE
IRs and their associated 95% exact Poisson confidence intervals
(CIs), as well as the pooled TEE IR, through a random-intercept
generalized linear mixed model based on a Poisson distribution.6
Stratified analyses according to study design (prospective vs
retrospective), publication year (1980-2004, 2005-2010, or 2011-
2016), hemophilia type (congenital vs acquired), and treatment
modality (on demand, prophylaxis, or surgery) were conducted. A
metaregression model was fitted to test for the effect of publication
year on the pooled TEE IR.
We performed all analyses with R software (version 3.4.0; R Foundation
for Statistical Computing, Vienna, Austria) through themetarate function
of the meta package.7
Results
We identified a total of 144 articles through the electronic literature
search. After the exclusion of 94 nonrelevant references, 50 articles
were fully evaluated for inclusion in the meta-analysis, with other 11
additional articles identified through review of reference lists of
retrieved articles. Of the 61 fully evaluated publications, 39 studies
with safety data related to the use of AICC in patients with
congenital hemophilia with inhibitors or acquired hemophilia were
included in the meta-analysis2,3,5,8-43 (Figure 1).
The studies included2,3,5,8-43 were published from 1980 to 2016 and
provided information on safety related to 678  447 AICC infusions (7291
as on-demand treatment,2,5,8-11,15-18,23,28,29,32,33,36,37,39,42,43 77 203 as
prophylaxis,13,18,21,26,31,33,39,41,43 3296 in surgery,14,17-20,22,24,27,30,34,38
and 590657 with unmentioned treatment modalities3,12,25,35,40)
in .750 patients with inhibitors. Of 39 included studies,2,3,5,8-43
5 were controlled randomized clinical trials,2,5,9,33,39 10 were uncon-
trolled prospective studies,8,10,11,25,28,31,38,40,42,43 and the remaining
24 were retrospective studies.3,12-24,26,27,29,30,32,34-37,41 A majority
of the studies (69%) included only patients with congenital
hemophilia,2,5,8-11,13,16,18,20-33,36,37,39,41 and 10% only patients with
acquired hemophilia.15,17,40,42 In the remaining 21% of studies
involving both patients with acquired and those with congenital
hemophilia,3,12,14,19,34,35,38,43 it was not possible to differentiate
the number of infusions administered for 1 or the other condition,
except in 1 study.
In the overall included 39 studies,2,3,5,8-43 46 TEEs were reported: 13
disseminated intravascular coagulations, 11 myocardial infarctions, 4
pulmonary embolisms, 3 thrombotic cerebrovascular accidents, 3
deep vein thromboses, 3 superficial vein thromboses, 6 unspecified
thromboses (unreported locations), and 3 fibrinogen reductions. No
thrombotic microangiopathic events were reported. Of the 39 included
studies, 31 (79%) reported no TEEs. The pooled TEE estimated IR
was 2.87 (95% CI, 0.32-25.40) per 100 000 AICC infusions
(Figure 2), with significant heterogeneity among studies (P , .01).
When stratifying for retrospective3,12-24,26,27,29,30,32,34-37,41 and pro-
spective studies,2,5,8-11,25,28,31,33,38-40,42,43 35 TEEs per 649 343
AICC infusions (pooled IR, 5.42 per 100 000 infusions; 95% CI,
0.92-31.82) and 11 TEEs per 29 104 AICC infusions (pooled IR, 1.09
11 additional papers identified through review of reference lists
of the retrieved articles
50 full-text papers retrieved for detailed evaluation
61 full text articles assessed for eligibility
39 studies finally included in the meta-analysis
144 papers identified through PubMed search (March 23th 2017)
22 articles excluded after full-text evaluation: no safety data
(n=12), multiple publications on the same cohort (n=7), in-
vivo/ex-vivo studies (n=3)
94 papers excluded: title and/or abstract not relevant for the end
point of the study (n=11), review articles (n=50), case-reports (n=1),
animal studies (n=2), others (n=30)
Figure 1. Flow diagram of study selection process.
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per 100 000 infusions; 95% CI, 0.01-238.77) were reported,
respectively. We further stratified the studies according to year of
publication to evaluate a potential time effect by defining 3 groups of
studies: from 1980 to 2004 (10 studies3,8-16), 2005 to 2010 (17
studies2,5,17-31), and 2011 to March 2017 (12 studies32-43). The
pooled IRs were 5.46 (95%CI, 3.39-8.87), 0.51 (95%CI, 0-2806.06),
and 8.30 (95% CI, 0.49-139.33) per 100 000 AICC infusions,
respectively, with no statistically significant effect of publication year
on TEE IR as evaluated by the metaregression model (P 5 .18).
The pooled TEE IR in patients with acquired hemophilia15,17,40,42,43
was 287.79 (95% CI, 31.04-2668.08) per 100 000 AICC
infusions, whereas in patients with congenital hemo-
philia,2,5,8-11,13,16,18,20-33,36,37,39,41,43 it was ,0.01 per 100 000
infusions. Moreover, the pooled IR in patients treated on demand
with AICC2,5,8-11,15-18,23,28,29,32,33,36,37,39,42,43 was 5.09 (95%
CI, 0.01-1795.60) per 100 000 infusions, whereas in patients treated
with prophylaxis,13,18,21,26,31,33,39,41,43 no TEEs were reported.
When considering 11 studies in patients with hemophilia with inhibitors
undergoing surgery,14,17-20,22,24,27,30,34,38 5 TEEs were reported
(Table 1), with a pooled IR of 112.03 (95% CI, 24.66-509.08) per
100 000 AICC infusions.
Discussion
In summary, the overall pooled IRwas lower than 3 TEEs per 100 000
AICC infusions, confirming previous figures reported in smaller and
retrospective cohorts.3,12 Stratified analysis showed low TEE
incidence in patients with congenital hemophilia compared with
those with acquired hemophilia. This finding can probably be
explained by the potential presence of other thrombotic risk factors
in patients with acquired hemophilia A.44-46 Interestingly, no TEEs
were reported during prophylaxis with AICC (ie, repeated AICC
exposure for long periods of time with the consequent supernormal
levels of factor X and prothrombin and increased thrombin generation
and endogenous thrombin potential).4
To estimate how many AICC infusions to which a single patient with
hemophilia with inhibitors would be exposed during his or her lifetime,
we applied the prophylactic and on-demand regimens reported in the
Pro-FEIBA clinical trial33 to a time horizon of 70 years. We estimated
TEEs incidence rate x 100,000
AICC infusions
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Figure 2. Forest plot for the meta-analysis of TEE IR in patients with congenital hemophilia with inhibitors or acquired hemophilia exposed to AICC. Results
are expressed per 100  000 AICC infusions.
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that a patient treated with AICC prophylaxis would receive in his or her
lifetime 203 infusions per year (183 for prophylaxis and 20 to manage
10 breakthrough bleeds), corresponding to 14 210 infusions in 70
years of treatment. A patient treated on demand would experience 53
AICC infusions per year to manage 26.2 bleeds (ie, 3710 infusions in
70 years). This information is useful to understand the possible
impact of the TEE IR estimated in our analysis.
We chose to include only data from published clinical trials, non-
interventional prospective studies, and retrospective studies to obtain
reliable information on exposure to AICC, which would allow us to
estimate the IR of TEEs according to number of infusions. Case reports
and spontaneous reports were not considered unless previously
included in published studies, as was the case for the studies by
Ehrlich et al12 and Aledort.3 Case reports were not included in themeta-
analysis, because they cannot provide a reliable estimate of exposure to
AICC, and consequently of the IR of TEEs, being specifically focused on
describing a single event without considering all treated patients who
did not experience any TEEs.47,48 Because of the nature of these 2
studies by Ehrlich et al12 and Aledort,3 which were based on published
and unpublished spontaneously reported TEEs documented through
the Baxter BioScience Pharmacovigilance Program and the US Food
and Drug Administration MedWatch databases, respectively, we
carried out a sensitivity analysis by removing them; the pooled IR then
decreased to 1.13 (95% CI, 0.04-35.05).
In conducting a meta-analysis based on published aggregated data
without access to individual patient data, we could not address potential
confounders or evaluate associated risk factors (eg, ICC dose). A large
cohort study or individual patient-level meta-analysis should be
performed to adjust the TEE IR for confounders or associated risk
factors. However, because congenital and acquired hemophilia are rare
diseases, and TEEs occurring in those receiving AICC even rarer, such
study designs would require longer times and multicenter collabora-
tions, which can often be difficult and resource demanding. Neverthe-
less, our analysis showed a higher incidence of TEEs in patients with
acquired hemophilia, in whom the potential association between TEEs,
age, and comorbidities might play a role, and in those with congenital
hemophilia who had undergone surgery.49
Because TEEs are rare, the classic meta-analytic model based on the
inverse variance approach could not be fitted. Data were analyzed with
a generalized linear mixed model based on a Poisson distribution6 to
account for the presence of sparse data, thus avoiding the use of a
correction factor for studies reporting 0 events; however, CIs were
somewhat wide because of the small number of TEEs reported in the
39 studies included in the meta-analysis.
No thrombotic microangiopathic events were reported. However, a
recently published article50 reporting results from the HAVEN 1 clinical
trial in patients with hemophilia A and inhibitors treated prophylactically
with emicizumab described 5 severe adverse events (2 thromboembolic
events and 3 thrombotic microangiopathies), which occurred in 5 of 28
patients to whom AICC was administered as rescue therapy for the
treatment of breakthrough bleeds. The reported thrombotic micro-
angiopathies were diagnosed as hemolytic uremic syndromes. Hemo-
lytic uremic syndromes such as those observed in the HAVEN 1 study
had never been observed with AICC or published before. Moreover, the
overall frequency of TEEs observed in that study (1 event per 13-52
estimated infusions) seems higher than that in any other published study.Ta
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In conclusion, our systematic review and meta-analysis of published
study data provide a comprehensive and exhaustive estimate of the
overall, 40-year thromboembolic safety profile of AICC in patients
with hemophilia with inhibitors, showing that AICC is associated
with a low incidence of TEEs.
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